Toll Free: 1-888-928-9744

Cataract - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cataract - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cataract - Pipeline Review, H2 2016, provides an overview of the Cataract (Ophthalmology) pipeline landscape.

Cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred or dim vision, increasing difficulty with vision at night, fading or yellowing of colors, double vision in a single eye and frequent prescription changes in eye wear. Risk factors include age, diabetes, drinking excessive amounts of alcohol, high blood pressure, obesity and smoking. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cataract - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cataract (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cataract (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Cataract and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Cataract.

Cataract (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cataract (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Cataract (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cataract (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cataract (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Cataract (Ophthalmology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cataract (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cataract (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Cataract Overview 6
Therapeutics Development 7
Pipeline Products for Cataract - Overview 7
Pipeline Products for Cataract - Comparative Analysis 8
Cataract - Therapeutics under Development by Companies 9
Cataract - Therapeutics under Investigation by Universities/Institutes 10
Cataract - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Cataract - Products under Development by Companies 13
Cataract - Products under Investigation by Universities/Institutes 14
Cataract - Companies Involved in Therapeutics Development 15
EyeGate Pharmaceuticals, Inc. 15
Genisphere LLC 16
Omeros Corporation 17
Plex Pharmaceuticals, Inc. 18
Cataract - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
dexamethasone acetate - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
GL-249 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
lanosterol - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecule for Non-Surgical Cataracts and Multiple Sclerosis - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecule to Antagonize GPR161 for Central Nervous System Disorders, Oncology and Ophthalmology - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
VP-1001 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Cataract - Dormant Projects 39
Cataract - Discontinued Products 40
Cataract - Product Development Milestones 41
Featured News & Press Releases 41
Sep 07, 2016: Plex Pharmaceuticals awarded $299,173 NIH Phase I SBIR grant funding to find non-surgical treatments for Cataracts 41

Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43
List of Tables

Number of Products under Development for Cataract, H2 2016 7
Number of Products under Development for Cataract - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Cataract - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2016 15
Cataract - Pipeline by Genisphere LLC, H2 2016 16
Cataract - Pipeline by Omeros Corporation, H2 2016 17
Cataract - Pipeline by Plex Pharmaceuticals, Inc., H2 2016 18
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
Cataract - Dormant Projects, H2 2016 39
Cataract - Discontinued Products, H2 2016 40 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify